Oruka Therapeutics (NASDAQ:ORKA) Stock Rating Upgraded by Wall Street Zen

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Thursday.

Several other equities research analysts have also recently weighed in on the stock. Wolfe Research assumed coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 target price for the company. BTIG Research raised Oruka Therapeutics to a "strong-buy" rating and set a $44.00 price target for the company in a report on Thursday, May 22nd. HC Wainwright reissued a "buy" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, February 7th. Finally, Wedbush restated an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, May 15th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $40.38.

Oruka Therapeutics Stock Performance

Shares of ORKA traded up $0.46 during mid-day trading on Thursday, hitting $11.41. The company's stock had a trading volume of 85,775 shares, compared to its average volume of 225,171. The stock's 50-day moving average is $9.78 and its two-hundred day moving average is $14.01. The firm has a market capitalization of $427.20 million, a PE ratio of -1.82 and a beta of 0.25. Oruka Therapeutics has a one year low of $5.49 and a one year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. Analysts expect that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Oruka Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ORKA. Vanguard Group Inc. raised its holdings in shares of Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after buying an additional 1,572,853 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Oruka Therapeutics by 374.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company's stock worth $25,730,000 after acquiring an additional 1,047,245 shares in the last quarter. FMR LLC lifted its holdings in shares of Oruka Therapeutics by 17.7% during the fourth quarter. FMR LLC now owns 5,512,300 shares of the company's stock valued at $106,883,000 after acquiring an additional 830,000 shares during the period. Braidwell LP lifted its holdings in shares of Oruka Therapeutics by 122.5% during the fourth quarter. Braidwell LP now owns 1,147,676 shares of the company's stock valued at $22,253,000 after acquiring an additional 631,950 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in shares of Oruka Therapeutics by 259.7% in the 4th quarter. Janus Henderson Group PLC now owns 849,410 shares of the company's stock valued at $16,415,000 after purchasing an additional 613,294 shares in the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.